Active Stocks: IsoRay, CombiMatrix, Lakeland Industries, Tenet Healthcare, Pluristem Therapeutics Print E-mail
By Marilyn Mullen   
Tuesday, 07 October 2014 14:38

U.S. stock indexes are following other global markets lower in early trading. European stocks fell after Germany reported the biggest monthly drop in industrial production in five years. Asian markets mostly fell after the World Bank trimmed its Asian growth forecast.

The Dow Jones industrial average fell 132 points, or 0.8 percent, to 16,858. The Standard and Poor's 500 index fell 15 points, or 0.8 percent, to 1,949. The Nasdaq composite fell 37 points, or 0.8 percent, to 4,417.


Shares of nano cap IsoRay, Inc.(NYSEMKT:ISR) jump on a 5x surge in volume in response to the company's announcement of positive results from a brain tumor procedure in Peru.A neurosurgeon in Lima implanted a Cesium-131 seed via a stereotactic implant in a seven-year-old girl with an inoperable glioblastoma brain tumor. The 2.7 cm tumor could not be surgically removed because it was too close to the brainstem. Instead, the surgeon implanted a Cesium-131 seed directly into the tumor. Ten weeks later, the tumor had shrunk 70% and the girl was back at school.

Shares of thinly-traded nano cap CombiMatrix Corp(NASDAQ:CBMX) rise on light volume in response to its announcement that Q3's prenatal testing volume will be up 71% yoy. Total microarray testing volumes for the quarter are expected to be up 24%.

Disposable protective clothing maker LAKE jumps on a 4x surge in volume in an Ebola-stoked move. The company makes HAZMAT clothing that would be in heightened demand if the outbreak goes global.

Tenet Healthcare (NYSE:THC) subsidiary Conifer Health Solutions acquires physician practice management solutions provider SPi Healthcare for $235M. The transaction enables Conifer to expand its Revenue Cycle Management (RCM) services to the physician practices.

Pluristem Therapeutics (NASDAQ:PSTI) fends off a challenge from an unnamed cell therapy company to its European patent No. EP2200622 titled, "Adherent Cells From Adipose Or Placenta Tissues And Use Thereof In Therapy. "The European Patent Office concluded that the company's patent, whose claims cover the treatment of ischemia with adherent placental cells which are propagated using a 3D culture, is valid.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus